GPCM
VYNE icon

Granite Point Capital Management’s VYNE Therapeutics VYNE Stock Holding History

Granite Point Capital Management’s Portfolio VYNE Stock Details VYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-113
Closed -$304K – 143
2018
Q1 		$304K Buy
+113
New +$275K 0.03% 95

Other funds holding VYNE

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

Granite Point Capital Management's VYNE Position: Q2 2018 in Review

Granite Point Capital Management sold out of VYNE Therapeutics (VYNE) in Q2 2018, closing a stake of 113 shares — an estimated $304K sold.

Granite Point Capital Management first reported a position in VYNE in Q1 2018 and held it in 1 quarter. The position peaked at $304K in Q1 2018. 48 funds tracked by Wall St. Rank hold VYNE as of Q2 2018.

  • Granite Point Capital Management reported no remaining VYNE Therapeutics position as of Q2 2018 after selling out during the quarter.
  • Granite Point Capital Management sold 113 VYNE Therapeutics shares in Q2 2018, an estimated $304K.
  • Granite Point Capital Management first reported a position in VYNE Therapeutics in Q1 2018 and held it in 1 quarter.
  • Granite Point Capital Management's VYNE Therapeutics position peaked at $304K in Q1 2018.
  • 48 funds tracked by Wall St. Rank held VYNE Therapeutics as of Q2 2018.

Based on Granite Point Capital Management's 13F filing for Q2 2018, filed 13 Aug 2018.